T. Spalding

发表

Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease.

K. Mcfarland, T. Spalding, D. Hubbard, 2013, ACS chemical neuroscience.

Allosteric modulation of G-protein coupled receptors.

A. A. Jensen, T. Spalding, Anders A Jensen, 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains.

M. Brann, T. Spalding, E. Burstein, 1996, Biochemical pharmacology.

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

A. Levey, H. Meltzer, U. Hacksell, 2004, Psychopharmacology.

Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation

M. Brann, T. Spalding, Jian-Nong Ma, 2006, Molecular Pharmacology.

Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist

U. Hacksell, D. Weiner, M. Brann, 2004, Journal of Pharmacology and Experimental Therapeutics.

Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins.

M. Brann, T. Spalding, E. Burstein, 1997, Molecular pharmacology.

Homologous mutations near the junction of the sixth transmembrane domain and the third extracellular loop lead to constitutive activity and enhanced agonist affinity at all muscarinic receptor subtypes.

D. J. Ford, T. Spalding, E. Burstein, 2002, The Journal of pharmacology and experimental therapeutics.

Constitutive activation of muscarinic receptors by the G‐protein Gq

M. Brann, T. Spalding, E. Burstein, 1995, FEBS letters.

Functional Importance of the Ala116–Pro136 Region in the Calcium-sensing Receptor

M. Brann, P. O'Hara, P. Krogsgaard‐Larsen, 2000, The Journal of Biological Chemistry.

Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6.

J. W. Wells, M. Brann, T. Spalding, 1997, Biochemistry.

Amino Acid Side Chains That Define Muscarinic Receptor/G-protein Coupling

M. Brann, T. Spalding, E. Burstein, 1996, The Journal of Biological Chemistry.

Structure-Function of Muscarinic Receptor Coupling to G Proteins

M. Brann, D. Hill-Eubanks, T. Spalding, 1995, The Journal of Biological Chemistry.

Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.

N. Gray, Jianwei Che, P. Ren, 2008, Bioorganic & medicinal chemistry letters.

Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.

N. Gray, Jianwei Che, P. Ren, 2009, Bioorganic & medicinal chemistry letters.

Discovery of 2-amino-6-carboxamidobenzothiazoles as potent Lck inhibitors.

Shenlin Huang, R. Romeo, M. Sandberg, 2008, Bioorganic & medicinal chemistry letters.

Discovery of novel peptide/receptor interactions: identification of PHM-27 as a potent agonist of the human calcitonin receptor.

M. Brann, N. Nash, E. Currier, 2004, Biochemical pharmacology.

Structure/function relationships of a G-protein coupling pocket formed by the third intracellular loop of the m5 muscarinic receptor.

M. Brann, T. Spalding, E. Burstein, 1998, Biochemistry.

Interactions of Muscarinic Receptors with the Heterotrimeric G Proteins Gq and G12: Transduction of Proliferative Signals

B. Conklin, M. Brann, H. Bräuner‐Osborne, 1997, Journal of neurochemistry.

Pharmacological Characterization of AC-90179: a Selective 5-HT 2A Receptor Inverse Agonist

U. Hacksell, D. Weiner, M. Brann, 2004 .

Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.

J. Wityak, E. Saez, R. Epple, 2010, Journal of medicinal chemistry.

The Second Intracellular Loop of the m5 Muscarinic Receptor Is the Switch Which Enables G-protein Coupling*

M. Brann, T. Spalding, E. Burstein, 1998, The Journal of Biological Chemistry.

Constitutive Activity of Muscarinic Acetylcholine Receptors

T. Spalding, E. Burstein, 2006, Journal of receptor and signal transduction research.

Discovery of an ectopic activation site on the M(1) muscarinic receptor.

U. Hacksell, M. Brann, E. Currier, 2002, Molecular pharmacology.

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.

M A Geyer, M. Geyer, K. Krebs-Thomson, 2001, The Journal of pharmacology and experimental therapeutics.

Identification of a Ligand-dependent Switch within a Muscarinic Receptor*

M. Brann, T. Spalding, E. Burstein, 1998, The Journal of Biological Chemistry.

Structure of a G-protein-coupling Domain of a Muscarinic Receptor Predicted by Random Saturation Mutagenesis (*)

M. Brann, D. Hill-Eubanks, H. Bräuner‐Osborne, 1996, The Journal of Biological Chemistry.

Studies of the Pharmacology, Localization, and Structure of Muscarinic Acetylcholine Receptors a

M. Brann, D. Hill-Eubanks, T. Spalding, 1993, Annals of the New York Academy of Sciences.

Studies on muscarinic receptors using nitrogen mustards

E. Hulme, T. Spalding, N. Birdsall, 1993 .

Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis.

M. Brann, D. Hill-Eubanks, T. Spalding, 1995, The Journal of pharmacology and experimental therapeutics.

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

K. Mcfarland, D. Bonhaus, J. Lameh, 2010, Neuropharmacology.

Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout.

D. Weiner, M. Brann, F. Piu, 2006, Current pharmaceutical design.

Constitutively active muscarinic receptors.

T. Spalding, E. Burstein, 2001, Life sciences.

Functional importance of the Ala(116)-Pro(136) region in the calcium-sensing receptor. Constitutive activity and inverse agonism in a family C G-protein-coupled receptor.

M. Brann, P. Krogsgaard‐Larsen, H. Bräuner‐Osborne, 2000, The Journal of biological chemistry.

N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta.

Peter Tontonoz, Tove Tuntland, Ansgar Brock, 2007, Journal of medicinal chemistry.

Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors.

E C Hulme, E. Hulme, C. Curtis, 1994, The Journal of biological chemistry.

Exploring the potential for subtype-selective muscarinic agonists in glaucoma.

M. Brann, T. Spalding, E. Woldemussie, 2001, Life sciences.

Discovery of 2-amino-6-carboxamidobenzothiazoles as potent Lck inhibitors.

Shenlin Huang, R. Romeo, T. Spalding, 2008, Bioorganic & medicinal chemistry letters.

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

K. Mcfarland, D. Bonhaus, J. Lameh, 2010, Neuropharmacology.